David Dow

David Dow is currently the Global Development Leader for Oncology at Telix Pharmaceuticals Limited, overseeing asset development from preclinical stages through Phase 3 exit. Previously, David served as a Senior Director of Allogeneic Research at Adaptimmune, where they led a large team and made significant advancements toward IND and Phase 1 programs. With a strong background in genomics and cancer immunotherapy, David has held various leadership roles at GlaxoSmithKline, Open Targets, and the University of Cambridge, contributing to cutting-edge projects in targeted therapies and cell systems. David is pursuing a Ph.D. in Genomic Medicine at the University of East Anglia and has additional education from the University of Oxford and the Royal College of Pathologists.